U.S. markets closed

ASLAN Pharmaceuticals Limited (ASLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7000-0.0500 (-1.82%)
At close: 4:00PM EDT
2.7400 +0.04 (1.48%)
After hours: 04:33PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.7500
Bid2.6700 x 1300
Ask2.7400 x 1200
Day's Range2.6100 - 2.8102
52 Week Range1.2600 - 6.7500
Avg. Volume884,209
Market Cap187.706M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-0.4750
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures

    ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures

    Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secur

  • Why ASLAN Pharmaceuticals Blasted Higher on Friday
    Motley Fool

    Why ASLAN Pharmaceuticals Blasted Higher on Friday

    Shareholders of ASLAN Pharmaceuticals (NASDAQ: ASLN) are primed for a good weekend. Raycroft believes the shares are worth $8 apiece, more than 150% higher than Thursday's closing price. ASLAN, a clinical-stage immunology biotech, only has two treatments in development.

  • TheStreet.com

    Singapore's Aslan Pharma Gets Buy Rating from Jefferies

    'ASLN's '004 is a fast follower, targeting an understood, de-risked path in atopic dermatitis [eczema],' said Jefferies analyst Maury Raycroft.